» Innovative and Sustainable Pipeline
» Solutions to Pharma R&D Cost and Efficiency
Founded in 2001, TaiGen Biotechnology Co., Ltd. (“TaiGen Taiwan” or “TaiGen”) is
a research-based and product-driven pharmaceutical company engaging in the
development of novel therapeutics for infectious diseases, cancer and
diabetes-related complications. TaiGen has a wholly-owned Beijing subsidiary
with a proven capacity to conduct clinical trials and related registrations.
There are 77 FTEs including 70% R&D staffs in Taipei and Beijing offices.
In 2008, TaiGen Taiwan completed a share swap with TaiGen
Biopharmaceuticals Holdings Limited (“TaiGen Cayman” or “TaiGen”), and has
become a fully owned subsidiary of TaiGen Cayman. TaiGen Cayman will be the
legal entity for TaiGen’s IPO; as of March 2012, there are approx. 572 million
shares issued and outstanding, each with par value of US$0.001.
TaiGen has raised a total of US$114 million since its inception;
principle shareholders include Taiwan’s National Development Fund, Yuen Foong Yu
(YFY) Group, China Development Industrial Bank, Shin Kong Life Insurance, Cathay
Life Insurance, China Steel Corporation, Taiwan Sugar Corporation, Yao-Hwa Glass
Management Commission, and Taiwan Global BioFund.
TaiGen has built a fully-integrated pharmaceutical company by pursuing a business
strategy that capitalizes on the management team's extensive expertise in drug
discovery, development, global regulatory approval processes, and
commercialization in China. Senior executives at TaiGen were recruited from both
major pharmaceutical/biotech companies in the West as well as from Asian-based
multinational companies. This unique expertise allows the company to focus on
in-licensing late-stage innovative drugs targeting Asian-prevalent diseases to
complement its own internal research programs as well as to partner its organic
drug development programs. In addition, TaiGen has formed marketing alliances to
capture the rapidly-expanding Asian pharmaceutical market.
TaiGen's current pipeline includes "first-in-class" and "best-in-class" products
with worldwide IP rights.
» The TaiGen Business model:
